• 12 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
    Accurate identification of prostate cancer Gleason grade group remains an important component of the initial management of clinically localized disease. However, Gleason score upgrading (GSU) from b [...] Read more.
    Shayan Smani ... Michael S. Leapman
    Published: July 30, 2024 Explor Target Antitumor Ther. 2024;5:981–996
    DOI: https://doi.org/10.37349/etat.2024.00259
    View:485
    Download:21
    Times Cited: 0
    Open Access
    Commentary
    The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC)
    The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic urothelial cancer (mUC) has rapidly changed in the last year alone. Maintenance avelumab remains  [...] Read more.
    Minira Aslanova ... Jeanny B. Aragon-Ching
    Published: July 29, 2024 Explor Target Antitumor Ther. 2024;5:971–980
    DOI: https://doi.org/10.37349/etat.2024.00258
    This article belongs to the special issue Emerging Molecular Targets and Therapies of Genitourinary Tumors
    View:538
    Download:39
    Times Cited: 0
    Open Access
    Review
    Hepatobiliary complications of immune checkpoint inhibitors in cancer
    Immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of cancer therapy. Over the last decade, both their primary focus in trials and clinical application have exponentially ri [...] Read more.
    Donna Zhuang ... Stephen Riordan
    Published: July 26, 2024 Explor Target Antitumor Ther. 2024;5:955–970
    DOI: https://doi.org/10.37349/etat.2024.00257
    This article belongs to the special issue Immune Checkpoint Therapy and Biomarkers in Cancer
    View:498
    Download:13
    Times Cited: 0
    Open Access
    Review
    A narrative review on perioperative systemic therapy in non-small cell lung cancer
    Non-small cell lung cancer (NSCLC) that is operable still carries a high risk of recurrence, approaching 50% of all operable cases despite adding adjuvant chemotherapy. However, the utilization of i [...] Read more.
    Robert Hsu ... David J. Benjamin
    Published: July 26, 2024 Explor Target Antitumor Ther. 2024;5:931–954
    DOI: https://doi.org/10.37349/etat.2024.00256
    This article belongs to the special issue Integrated Approaches for Non-Small-Cell Lung Cancer
    View:935
    Download:20
    Times Cited: 0
    Open Access
    Case Report
    Oligometastatic esophageal cancer cured by systemic therapy combined with radiotherapy to primary tumor and metastasis (metastasis-directed therapy)—small case series
    The prognosis of metastatic esophageal cancer (EC) remains poor with an average life expectancy of around 9–12 months with standard systemic chemotherapy. The concept of oligometastatic disease (O [...] Read more.
    Mohan Hingorani, Hannah Stubley
    Published: July 26, 2024 Explor Target Antitumor Ther. 2024;5:921–930
    DOI: https://doi.org/10.37349/etat.2024.00255
    View:443
    Download:13
    Times Cited: 0
    Open Access
    Review
    Therapy-induced senescence in breast cancer: an overview
    Outcomes for women with breast cancer have improved dramatically in recent decades. However, many patients present with intrinsic drug resistance and others are initially sensitive to anti-cancer dr [...] Read more.
    Suraj Narayanan Chembukavu, Andrew J Lindsay
    Published: July 25, 2024 Explor Target Antitumor Ther. 2024;5:902–920
    DOI: https://doi.org/10.37349/etat.2024.00254
    This article belongs to the special issue Mechanisms of Targeted Therapy Resistance and Reversal Strategies
    View:891
    Download:22
    Times Cited: 0
    Open Access
    Review
    The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications
    Splenic marginal zone lymphoma (SMZL) is a rare, predominantly indolent B-cell lymphoma constituting fewer than 2% of lymphoid neoplasms. However, around 30% of patients have [...] Read more.
    Amatta Mirandari ... Jonathan C. Strefford
    Published: July 23, 2024 Explor Target Antitumor Ther. 2024;5:877–901
    DOI: https://doi.org/10.37349/etat.2024.00253
    View:593
    Download:17
    Times Cited: 0
    Open Access
    Review
    Regulatory RNAs: role as scaffolds assembling protein complexes and their epigenetic deregulation
    Over the last decade, immune checkpoint inhibitors (ICIs) have dramatically improved the systemic treatment of multiple solid tumour types. However, they can also induce inflammation in an extensive [...] Read more.
    Palmiro Poltronieri
    Published: July 22, 2024 Explor Target Antitumor Ther. 2024;5:841–876
    DOI: https://doi.org/10.37349/etat.2024.00252
    This article belongs to the special issue Cancer Epigenetics: Implications for Novel Therapeutic Strategies
    View:529
    Download:27
    Times Cited: 0
    Open Access
    Review
    It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
    Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer [...] Read more.
    Ken Akao ... Kazuyoshi Imaizumi
    Published: July 19, 2024 Explor Target Antitumor Ther. 2024;5:826–840
    DOI: https://doi.org/10.37349/etat.2024.00251
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:651
    Download:20
    Times Cited: 0
    Open Access
    Case Report
    Immune checkpoint inhibitor-induced cholangitis—a three-case series
    Over the last decade, immune checkpoint inhibitors (ICIs) have dramatically improved the systemic treatment of multiple solid tumour types. However, they can also induce inflammation in an extensive range of normal tissues types.  [...] Read more.
    Simon Gray ... Anna Olsson-Brown
    Published: July 19, 2024 Explor Target Antitumor Ther. 2024;5:818–825
    DOI: https://doi.org/10.37349/etat.2024.00250
    View:360
    Download:9
    Times Cited: 0